Aeolus Pharmaceuticals IncOver The Counter Market:AOLS
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aeolus Pharmaceuticals Inc | 150.0 | 0.0x | --- |
Adynxx Inc | 580.0 | 0.0x | --- |
Seelos Therapeutics Inc | 170.0K | 0.0x | --- |
Drazcanna Inc | 164.2K | 0.0x | --- |
DNAPrint Genomics Inc | 640.0 | 0.0x | --- |
Regenerative Medical Technology Group Inc | 395.0K | 0.0x | --- |
Company Information
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The Company's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.
Contact Information
- Headquarters
- 27800 Medical Center RdMISSION VIEJO, CA, United States 92691
- Phone
- 949-485-9621
- Fax
- 919-558-8686
Executives
- Chairman of the Board, Chief Financial Officer
- David Cavalier
- President, Chief Executive Officer
- John Mcmanus
- Independent Director
- John Clerici
- Independent Director
- John Farah
- Independent Director
- Mitchell Kaye
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $150.00 |
|---|---|
Revenue (TTM) | $771.0K |
Shares Outstanding | 152.1M |
Aeolus Pharmaceuticals Inc does not pay a dividend. | |
Beta | 0.45 |
EPS | $-0.03 |
Book Value | $0.02 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -531.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
